CHRNA7 and ischemia: An important rationale for the therapeutic use of α7 nAChR agents arises from the fact that α7 nAChRs are ubiquitously expressed throughout the brain [62] including brain regions that are highly vulnerable to ischemia, such as cortex, striatum and hippocampus [63–66].